D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 92 Citations 38,316 574 World Ranking 5533 National Ranking 3085

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Disease

Ruben A. Mesa spends much of his time researching Myelofibrosis, Internal medicine, Surgery, Myeloid and Polycythemia vera. His Myelofibrosis research is multidisciplinary, incorporating perspectives in Essential thrombocythemia, Adverse effect and Anemia. His work deals with themes such as Gastroenterology and Oncology, which intersect with Internal medicine.

His Surgery research focuses on Splenectomy and how it relates to Perioperative. The concepts of his Myeloid study are interwoven with issues in Metaplasia, Myeloid leukemia, Bone marrow and Thrombocytosis. His Polycythemia vera study incorporates themes from European LeukemiaNet and Intensive care medicine.

His most cited work include:

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2498 citations)
  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis (1226 citations)
  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis (892 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Myelofibrosis, Polycythemia vera, Ruxolitinib and Essential thrombocythemia. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. Ruben A. Mesa combines subjects such as Myeloid, Anemia and Constitutional symptoms with his study of Myelofibrosis.

Within one scientific family, Ruben A. Mesa focuses on topics pertaining to Transplantation under Polycythemia vera, and may sometimes address concerns connected to Stem cell. His work in Ruxolitinib addresses subjects such as Adverse effect, which are connected to disciplines such as Discontinuation. Ruben A. Mesa has researched Essential thrombocythemia in several fields, including Bone pain and Acute leukemia.

He most often published in these fields:

  • Internal medicine (66.23%)
  • Myelofibrosis (59.37%)
  • Polycythemia vera (23.48%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (66.23%)
  • Myelofibrosis (59.37%)
  • Ruxolitinib (22.03%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Myelofibrosis, Ruxolitinib, Oncology and Gastroenterology. When carried out as part of a general Internal medicine research project, his work on Myeloproliferative neoplasm, Polycythemia vera, Essential thrombocythemia and Quality of life is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His Myelofibrosis research includes elements of Spleen, Anemia, Transplantation and Constitutional symptoms.

His Ruxolitinib study combines topics from a wide range of disciplines, such as Previously treated, Janus kinase inhibitor, Tolerability and Phases of clinical research. Ruben A. Mesa usually deals with Oncology and limits it to topics linked to Cytopenia and Surrogate endpoint. Ruben A. Mesa studied Gastroenterology and Adverse effect that intersect with Discontinuation.

Between 2018 and 2021, his most popular works were:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea (47 citations)
  • Oral Idasanutlin in Patients with Polycythemia Vera (28 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary areas of investigation include Internal medicine, Myelofibrosis, Ruxolitinib, Gastroenterology and Cohort. His Internal medicine study frequently links to adjacent areas such as Oncology. Myelofibrosis is a subfield of Bone marrow that Ruben A. Mesa investigates.

His Ruxolitinib research integrates issues from Thrombocytosis, Cancer research, Cell and Phases of clinical research. As a part of the same scientific study, Ruben A. Mesa usually deals with the Gastroenterology, concentrating on Stem cell and frequently concerns with Toxicity and Combination therapy. His Cohort research incorporates themes from Cancer, Clinical endpoint, Clinical trial, Absolute neutrophil count and Chemotherapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert.
Cancer Cell (2005)

3375 Citations

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy.
The New England Journal of Medicine (2012)

1678 Citations

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani.
The New England Journal of Medicine (2010)

1406 Citations

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti.
Blood (2008)

1228 Citations

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman.
Blood (2006)

1147 Citations

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka.
Blood (2007)

878 Citations

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes.
Journal of Clinical Oncology (2011)

850 Citations

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi.
The New England Journal of Medicine (2015)

663 Citations

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)

613 Citations

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

A. Tefferi;A. Pardanani;K. H. Lim;K. H. Lim;O. Abdel-Wahab.
Leukemia (2009)

534 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ruben A. Mesa

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 320

Alessandro M. Vannucchi

Alessandro M. Vannucchi

University of Florence

Publications: 241

Srdan Verstovsek

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center

Publications: 240

Paola Guglielmelli

Paola Guglielmelli

University of Florence

Publications: 157

Ross L. Levine

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Publications: 146

Animesh Pardanani

Animesh Pardanani

Mayo Clinic

Publications: 142

Claire N. Harrison

Claire N. Harrison

Guy's and St Thomas' NHS Foundation Trust

Publications: 136

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 123

Francesco Passamonti

Francesco Passamonti

University of Insubria

Publications: 117

Tiziano Barbui

Tiziano Barbui

Johns Hopkins University

Publications: 104

Terra L. Lasho

Terra L. Lasho

Mayo Clinic

Publications: 97

Stefan N. Constantinescu

Stefan N. Constantinescu

Ludwig Cancer Research

Publications: 95

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 87

Francisco Cervantes

Francisco Cervantes

University of Barcelona

Publications: 86

Mario Cazzola

Mario Cazzola

University of Pavia

Publications: 84

Giovanni Barosi

Giovanni Barosi

University of Pavia

Publications: 83

Trending Scientists

Sargur N. Srihari

Sargur N. Srihari

University at Buffalo, State University of New York

Aloysius K. Mok

Aloysius K. Mok

The University of Texas at Austin

Jie Xu

Jie Xu

University of Leeds

Mark Jaccard

Mark Jaccard

University of British Columbia

Bin Jiang

Bin Jiang

Chinese Academy of Sciences

Pascal M. Adjakple

Pascal M. Adjakple

InterDigital (United States)

Shaowen Cao

Shaowen Cao

Wuhan University of Technology

David T. Denhardt

David T. Denhardt

Rutgers, The State University of New Jersey

Lee J. T. White

Lee J. T. White

University of Stirling

J. Andrew Royle

J. Andrew Royle

United States Fish and Wildlife Service

Alan R. Saltiel

Alan R. Saltiel

University of California, San Diego

Timothy E. McGraw

Timothy E. McGraw

Cornell University

Dora E. Angelaki

Dora E. Angelaki

New York University

Michael Weiner

Michael Weiner

United States Department of Veterans Affairs

Jennifer G. Robinson

Jennifer G. Robinson

University of Iowa

Roman Jakobson

Roman Jakobson

Harvard University

Something went wrong. Please try again later.